Ertapenem, imipenem, meropenem, ceftriaxone, piperacillin, piperacillin-tazobactam, clindamycin, and metronidazole were agar dilution MIC tested against 431 anaerobes. Imipenem, meropenem, and ertapenem were the most active ␤-lactams (MICs at which 50% of the strains are inhibited [MIC 50 s], 0.125 to 0.25 g/ml; MIC 90 s, 1.0 to 2.0 g/ml). Time-kill studies revealed that ertapenem at two times the MIC was bactericidal for 9 of 10 strains after 48 h. The kinetics for other ␤-lactams were similar to those of ertapenem.
Clinically isolated anaerobes are becoming more drug resistant (4, 6) . Ertapenem (MK-0826) (1-3, 7, 11, 12 ) is a new, structurally unique, long-acting parenteral carbapenem. This study tested the antianaerobic activity of ertapenem by (i) comparing the MICs of ertapenem with those of imipenem, meropenem, ceftriaxone, piperacillin, piperacillin-tazobactam, clindamycin, and metronidazole against 431 anaerobes and (ii) testing the activities of all of the drugs against 10 anaerobes by time-kill studies.
The strains used were (i) 209 recent isolates from clinical trials with ertapenem obtained from Merck, Inc. (Rahway, N.J.) in Merck protocols 004, 016, 017, and 023 and (ii) 222 recent clinical isolates from our collection of species not included in the first group. All strains were isolated within 2 years of this study and were identified by standard methodology (10) . Agar dilution MIC tests were performed on 431 strains, and time-kill assays were performed on 10 organisms.
␤-Lactamase testing was done by nitrocefin disk (Cefinase; BBL Microbiology Systems, Cockeysville, Md.) (4) . Agar dilution MIC tests were done as recommended by the National Committee for Clinical Laboratory Standards (5), using brucella agar (Difco) with 5% sterile defibrinated sheep blood and inocula of 10 5 CFU/spot. Tazobactam was combined with piperacillin at a fixed concentration of 4.0 g/ml. For the 10 strains tested by time-kill (see Table 2 ), the microdilution MIC tests were done according to the recommendations of the National Committee for Clinical Laboratory Standards (5), using brucella broth (Difco) with 5% sterile defibrinated horse blood. Trays were inoculated with 10 6 CFU/ml. Incubation of plates and trays was done in an anaerobic chamber (Coy Laboratory Products) in 80% N 2 -10% H 2 -10% CO 2 . Standard quality control strains (Bacteroides fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, and Eubacterium lentum ATCC 43055) were included with each run.
Time-kill testing was done as described previously (8, 9) . Inocula were prepared inside the chamber by suspending five colonies from brucella blood agar plates in a tube containing 5 ml of prereduced brucella broth (Difco). A 100-l aliquot was delivered by syringe into each vial containing 2.9 ml of prereduced brucella broth with 5% laked horse blood cells, 5 g of hemin/ml, 1 g of vitamin K 1 /ml, and 1 ml of antibiotic dilution (prepared in prereduced brucella broth). All preparations and dilutions were prepared in the chamber. The vials were removed from the chamber and incubated for 48 h in a shaking water bath at 35°C (8, 9) . For metronidazole, where thorough prereduction is necessary, 200 l of Oxyrase (Mansfield, Ohio) solution was added (8, 9) . The antibiotic ranges were MIC, two times the MIC, and four times the MIC.
One antibiotic-free growth control was used in each experiment. Aliquots containing 100 l of diluted inoculum were added, with a final inoculum of 10 6 to 10 7 CFU/ml. The suspensions were incubated at 35°C in a shaking water bath, and viability counts (8, 9) were performed at 0, 6, 12, 24, and 48 h, with the plates incubated for 48 h inside the chamber. Data were analyzed by expressing viable counts as log 10 CFU per milliliter higher or lower than the original inoculum at zero hour. Bacteriostatic activity was defined as 0 to Ͻ3 ⌬log 10 CFU/ml, and bactericidal activity was defined as Ն3 ⌬log 10 CFU/ml at each time period compared to zero hour. Drug carryover was minimized by dilution as described previously (8, 9) . Kill kinetics data were analyzed by the Fisher exact test.
␤-Lactamase was detected in 124 of 133 (93.2%) of the B. fragilis group, 55 of 80 (68.8%) Prevotella-Porphyromonas strains, and 5 of 41 (12.2%) fusobacteria. All gram-positive strains were ␤-lactamase negative. The results of agar dilution MIC testing are presented in Table 1 . Imipenem, meropenem, and ertapenem were the most active ␤-lactams, with MICs at which 50% of the strains were inhibited (MIC 50 s) of 0.125, 0.125, and 0.25 g/ml and MIC 90 s of 1.0, 1.0, and 2.0 g/ml, respectively. Ertapenem, at Յ4.0 g/ml, inhibited 95.8% of all 431 anaerobes tested. The only strains consistently ertapenem resistant (for which the MICs were Ͼ16.0 g/ml) were lactobacilli (␤-lactamase negative), which are rare human pathogens. Ceftriaxone and piperacillin were active against only ␤-lactamase-negative strains, while piperacillin-tazobactam (11) .
e Actinomyces spp. (6) and Bifidobacterium spp. (8) . (Table 2) were within 1 dilution of the MIC 50 s (Table 1) , except for one B. fragilis strain (clindamycin MIC, 0.5 g/ml), one B. fragilis strain (piperacillin-tazobactam MIC, 0.25 g/ml); one B. thetaiotaomicron strain (piperacillin-tazobactam MIC, 2.0 g/ml); one Prevotella bivia strain (meropenem MIC, 0.25 g/ml; ceftriaxone and piperacillin MICs, 32.0 g/ml), one Prevotella intermedia strain (ceftriaxone MIC, 16.0 g/ml), one Fusobacterium nucleatum strain (ertapenem and meropenem MICs, 0.008 g/ml; ceftriaxone MIC, 0.125 g/ml), and one Clostridium perfringens strain (piperacillin MIC, 1.0 g/ml; metronidazole MIC, 4.0 g/ml).
Time-kill tests (Table 2) revealed that ertapenem at two times the MIC was bactericidal (99.9% killing) for 9 of 10 strains after 48 h, with 90% killing of all 10 strains after 24 h at two times the MIC. The one strain not killed by ertapenem after 48 h at two times the MIC was a Clostridium difficile strain, also not killed by imipenem but killed by meropenem at two times the MIC after 48 h. Kinetics for all ␤-lactams relative to the MIC were similar to those of ertapenem, with bactericidal activity at two times the MIC after 48 h. Clindamycin was bactericidal against 8 strains after 48 h at two times the MIC, with 90% killing of all 10 strains after 24 h at two times the MIC. Metronidazole was bactericidal against eight strains at two times the MIC after 24 h and against seven strains after 48 h. Clindamycin killed strains significantly more slowly (P Ͻ 0.05) than ertapenem at 6 and 12 h; no other statistically significant differences were found. Ertapenem is a new long-acting 1-␤-methyl carbapenem antibiotic with antibacterial activities comparable or superior to those of established agents against gram-positive and -negative organisms. Ertapenem has an antibacterial spectrum including common aerobic and anaerobic bacteria and organisms with extended-spectrum ␤-lactamases. Advantageous pharmacokinetics, including an extended half-life at 32 ␤ phase and improved stability to renal DHP-1, support development of this compound as a single once-daily-dosing agent in moderateto-severe community-acquired and mixed infections (2, 7, 11).
Wexler et al. (12) reported MICs similar to ours against 363 anaerobes, with Ն98% of strains susceptible to ertapenem, imipenem, and meropenem. In another recent study, the ertapenem MICs were similar to those reported here: ertapenem was uniformly active against all 1,001 isolates with the exception of 12 of 61 (20%) Bilophila wadsworthia strains, 3 lactobacilli, and 1 strain of Acidaminococcus fermentans (3). Our study confirms the antianaerobic activity of ertapenem by MIC and time-kill tests.
In summary, ertapenem showed low MICs and good kill kinetics against a wide variety of anaerobes. These data, together with the its spectrum of activity against aerobes and its favorable pharmacokinetics, make ertapenem a promising choice for treatment of mixed aerobic-anaerobic infections. Clinical studies will be necessary to validate these findings.
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